Andrew Altman – VP/GM Bioresearch Global Finance Leadership Meeting May 29, 2013

1. Andrew Altman – VP/GM Bioresearch Global Finance Leadership MeetingMay 29, 2013

2. Professional Background • Joined IDEXX April 29, 2013 • Capital Equipment Sales, Sales Mgt - 25 years • HPLC • LC/GC Mass Spectrometry • NMR • Imaging (MRI and PET) • CEO IT Imaging – Breast Cancer screening by MRI • VP/GM HPLC – Thermo Fisher • International organization – San Jose, CA, Basel CH, and Odense, DK • Multiple M&A activities including integration of $2.1B Dionex • Environmental and Food Safety

3. Business Philosophy • Customer Focused • Where can we add value? • Alignment – • Communication up, down and across the organization • No silos! • Measurable goals • Quarterly Scorecard Review • Empower employees to • Innovate • Solve problems • Sins of commission are easily forgiven, sins of omission are not

4. Personal Background • BS (Bio)-Chemistry & Economics - UC San Diego • Graduate work in protein chemistry & enzyme kinetics • Nuclear Magnetic Resonance and Mass Spectrometry • Married 27 years Christy – Event Coordinator • Sean 26 – Outdoor Educator • Cameron 23 – Business Analytics • Amanda 19 – Pre-Med • Domino 8 and Snickers 5

5. Domino and Snickers

6. BRM Positioning Statement IDEXX BioResearchprovides specialized diagnostic services and analyzers to support biomedical research organizations dedicated to the improvement of human and animal health. Unlike other specialized analytical and diagnostic services providers, IDEXX BioResearchprovides high level scientific and veterinary expertise that assists with data interpretation assuring researchers of thequality of animal health, the integrity of biological reagents, and the accuracy of diagnostic and preclinical testing.

7. BRM is NOT the Companion Animal Market

8. BioResearch Customers - Who We Serve? Organizations: • Academic institutions (universities, etc.), pharma/biotech companies, contract research organizations (CROs) Departments: • Comparative medicine, animal core facilities, purchasing, and any specific departments with ongoing biomedical research (biology, neurology, immunology, oncology, metabolic diseases, etc.) Persons/Roles: • Research scientists, lab managers, vivarium managers, lab animal vets, purchase agents.

9. Target Audiences

10. Key Goals for 2013 - #1 Alignment to One Brand RADIL PRECLINICAL • Scientific expertise • Name recognition • Innovation • Business Processes • Academic client base • Customer service • RADIL LIMS • Optimal health monitoring IDEXX Bioresearch • Consultative expertise • Scientific knowledge and support • Cutting edge innovation • Broad portfolio and comprehensive test menus • Broad client base • Industry leading data management + • Broad test menu • Pathology expertise • RealTime PCR • Pharma/Biotech client base • GCP capabilities • Customer service • Courier system + Instruments • Hematology portfolio • Sysmex partnership • Service & Support infrastructure (FTS, SmartService, etc.)

11. Key Goals for 2013 - #2 Zebrafish(Zf) Today: Near-term: The Vision: • Recent launch of Zf diagnostics • Suite of diagnostic offerings that provides the basis for Zf health monitoring • Client consultations provided by Zf expert • Ongoing R&D aimed at gaining a better understanding of Zf diseases and improving health monitoring • Expanded range of services for clients • New revenues from Zf testing • Opens doors to competitive take-away accounts for diagnostics, preclinical, and analyzer business IDEXX Bioresearch has an international reputation as the One-Stop-Shop for Zf needs. Known as: • The Lab for Zf health monitoring • The Experts on Zf diseases and Dx • The Source for Certified Zebrafish (CZf) • Zf with certified health and genetic status • Zf food • Zf informatics

12. Key Goals for 2013 - #3 Sharpen Commercial Execution Offering portfolio of best-in-class lab hematology Establishing ‘door-opener’ and ‘foundation’ with Zebrafish Establishing IDEXX as the optimal health monitoring company Comparable, best-in-class results, regardless of laboratory throughput needs Unprecedented flexibility for studies where hematology is routine Advanced features, including manual gating, available on both platforms Establishes IDEXX as the leader in lab hematology – with multiplier for other businesses IDEXX is the commercial leader in the nascent zebrafish diagnostics and health monitoring Establishing IDEXX as the expert in zebrafish diagnostics IDEXX research and education programs are opening doors and building awareness across product lines Establishing collaborations with government-sponsored zebrafish resources Opportunity for IDEXX to take first-mover advantage? • Revolutionary new products keep IDEXX at the forefront of technology and in customers’ minds for health monitoring • Opti Q/Opti HM – launched • Dry blood spot (June) • MFI IA bead sales (July) • Stat PCR (August) • Fecology (October) • Stat micro (Q4) • Through research and scientific presentations reinforce IDEXX’s leading position in the market • Multiplier for driving awareness across IDEXX’s product lines Fourth pillar beyond 2013: GLP acquisition drives a multiplier in GCP business –and expands specialized preclinical services menu

13. Key Goals for 2013 - #4 International Expansion Working: Near-term: Needs: • Commercial Team now in place; UK and Germany • New hire expertise in: • Hematology (ex-Sysmex) • Health Monitoring(Ex-CRL) • Expand commercial • Nordic • France • Opportunistic approach in APO • Brand recognition • Lead generation • EU Specific: • Price List • Web site • Lab Capacity in EU • Pre-Clinical Expertise • Quote and Deliver • GLP capability

14. Total BioResearch Financial History

15. Total BioResearch Strategic Plan P&L

16. BioResearch Revenue Shift 2013 – 2018 Labs BRM continues to be main driver of revenue growth, while shift to higher margin consumables drives margin improvement in out-years.

17. Revenue by Region

18. Questions ?

19. Backup

20. Sales Team Feedback: CompetitivenessWhat customer segmentation best describes the opportunity for pre-clinical and instrument sales – customers for which we can provide an end-to-end solution and those which benefit primarily from pre-clinical services or instruments? ProCyte a very good solution XTV less competitive for price Chemistry, other instruments a tactical gap Catalyst Dx validation, sample size, menu issues Price, research menu and GLP are gaps In-house competition In-house competition Bid process Not always applicable Awareness of offering lacking in market = Competitive= Not competitive

21. Four Tenets of Information Technology Strategy Vision: Provide connectivity between IDEXX and customers’ data management systems LDE (LabsDataExchange) ProCyte Dx workcell IV. Enable import of Charles River data into LDE to facilitatecustomer conversion VetLab Suite SYSMEX XT-V Customer’s LIS Research Connect/RADIL Online RADIL LIMS Preclinical I. Standardize analyzercommunication protocols (LIS ASTM 1394) to push data to customer LIS, BRM’s LDE(Data Acquisition Server) III. Enable querying of labs and analyzer data through customers’ LIS or RADIL ONLINE II. Connect RADIL LIMS, preclinical information intoLabs Data Exchange Focused on goals of integration – not specifics of solution architecture